CG Oncology (NASDAQ:CGON) Downgraded by Wall Street Zen to Sell

robot
Abstract generation in progress

Wall Street Zen downgraded CG Oncology (NASDAQ:CGON) from a “hold” to a “sell” rating. Despite this downgrade, the broader analyst consensus remains a “Moderate Buy” with an average price target of $69, and several other firms have recently raised their price targets. CG Oncology’s shares opened down slightly, but the company recently beat quarterly EPS expectations and has a solid market capitalization.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin